ACADIA faces securities fraud probe after trial data misses key endpoint, shares drop over 19%.

Pomerantz LLP is investigating ACADIA Pharmaceuticals for potential securities fraud following the company's announcement that its drug remlifanserin narrowly missed the primary endpoint in a Phase 2 trial for Alzheimer's disease psychosis. This news caused ACADIA's stock to fall nearly 13% on September 24, 2026, and further declined after analyst downgrades. The investigation focuses on whether ACADIA and its executives engaged in unlawful business practices related to the trial results disclosure. Investors affected are encouraged to contact Pomerantz LLP for potential class action participation.

ACADIA Pharmaceuticals shares are currently priced at USD 19.55 on Pluang as of Oct 08, 2026 21:15 WIB, showing a modest 0.51% decline in the last day. The stock has a market cap of $3.39 billion and a trading volume of 1,784,486 shares on the platform. Despite recent negative news, Pluang investors hold a typical position for about 77 days, with all current order activity being buy orders.